MannKind (NASDAQ:MNKD) Releases Earnings Results

MannKind (NASDAQ:MNKD - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.03 EPS for the quarter, hitting analysts' consensus estimates of $0.03, Zacks reports. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. The business had revenue of $76.78 million for the quarter, compared to analysts' expectations of $74.99 million.MannKind Price PerformanceNASDAQ MNKD traded down $0.20 during trading hours on Thursday, hitting $5.28. 2,371,934 shares of the company's stock traded hands, compared to its average volume of 1,924,207. The company has a market capitalization of $1.45 billion, a PE ratio of 75.37 and a beta of 1.28. MannKind has a 52-week low of $3.86 and a 52-week high of $7.63. The firm's 50-day moving average is $6.04 and its 200-day moving average is $6.28. Wall Street Analyst Weigh InSeveral analysts recently commented on the stock. Wells Fargo & Company initiated coverage on shares of MannKind in a research report on Friday, December 20th. They set an "overweight" rating and a $9.00 price target on the stock. StockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a research report on Wednesday. Wedbush reissued an "outperform" rating and issued a $11.00 price target on shares of MannKind in a report on Thursday. Finally, Royal Bank of Canada upgraded shares of MannKind from a "sector perform" rating to an "outperform" rating and upped their price target for the stock from $7.00 to $10.00 in a research report on Thursday, December 19th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $9.21.Check Out Our Latest Report on MannKindAbout MannKind (Get Free Report)MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.Featured StoriesFive stocks we like better than MannKindAbout the Markup CalculatorVolatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsHow to find penny stocks to invest and trade 2 Catalysts That Could Push NVIDIA Stock Up 30% This YearWhy Are These Companies Considered Blue Chips?Do GM Stock Buybacks Make the Stock Buyable For Investors?Should You Invest $1,000 in MannKind Right Now?Before you consider MannKind, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.While MannKind currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here